Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China

Vaccine

Volumn 30, Issue 47, 2012, Pages 6623-6627

  Shen, Liping ^a   Wang, Fuzhen ^a   Wang, Feng ^a   Cui, Fuqiang ^a   Zhang, Shuang ^a   Zheng, Hui ^a   Zhang, Yong ^a   Liang, Xiaofeng ^a   Bi, Shengli ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Endemic infection; Hepatitis B virus; Vaccine efficacy; Yeast derived recombinant vaccine

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHINA; CROSS-SECTIONAL STUDY; DRUG EFFICACY; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HUMAN; INFANT; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; YEAST;

CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; PREVALENCE; VACCINES, SYNTHETIC;

EID: 84867463171     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.067     Document Type: Article

References (18)

1. World Health Organization Hepatitis B 2000, World Health Organization, Geneva, Switzerland, http://www.who.Int/mediacentre/factsheets/fs204/en [accessed 02.06.10].
2. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34(6):1329-1339.
3. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., et al. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27(47):6550-6557.
4. Van der Sande M.A., Waight P., Mendy M., Rayco-Solon P., Hutt P., Fulford T., et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006, 193(11):1528-1535.
5. Van Herck K., Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis 2008, 27(10):861-869.
6. Liu C.B., Su C.A. The immunization of hepatitis B vaccine and its problems. Chin J Vac Immun 2004, 10(3):159-162.
7. Shen L.P., Zhang Y., Wang F., Zhang S., Yang J.Y., Fang K.X., et al. Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme. Epidemiol Infect 2011, 139(8):1159-1165.
8. Progress in hepatitis B prevention through universal infant vaccination - China, 1997-2006. Morb Mortal Wkly Rep 2007, 56(18):441-445.
9. Liu C.B., Xu Z.Y., Cao H.L., Sun Y.D., Chen D.B., Jin Q., et al. Sero-epidemiology of HBV infection in four province in China. Chin J Virol 1991, 7(Suppl):8-14.
10. Shen L.P., Yang J.Y., Mo Z.J., Li R.C., Li Y.P., Wei Z.L., et al. Study on the variations of hepatitis B virus status among people having received hepatitis B vaccine. Chin J Epidemiol 2007, 28(7):659-662.
11. Huang M.J., Fu T.Y., Xu Z.Y. The survey about the prevalence of hepatitis B virus. Shanghai J Prevent Med 1989, 1:16217.
12. Shen L.P., Yang J.Y., Mo Z.J., Li R.C., Li Y.P., Tan Y., et al. The study on immune efficacy of people vaccinated by hepatitis B recombinant yeast-derived vaccine for 6-9 years. J Appl Prevent Med 2006, 12(3):129-132.
13. Sun C.M., Jiang M.B., Wu W.S., Zhang G.H., Zhou N., Zhang H.Z., et al. Five years' immunogenicity of domestic HBV DNA recombinant vaccine. Prog Microbiol Immunol 2007, 35(2):1-3.
14. John T.J., Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations?. J Gastroenterol Hepatol 2005, 20(1):5-10.
15. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54(RR-16):1-31.
16. Chang M.H. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. J Clin Virol 2006, 36(Suppl 1):S45-S50.
17. Bialek S.R., Bower W.A., Novak R., Helgenberger L., Auerbach S.B., Williams I.T., et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008, 27(10):881-885.
18. Hammitt L.L., Hennessy T.W., Fiore A.E., Zanis C., Hummel K.B., Dunaway E., et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007, 25(39-40):6958-6964.